Mycosis fungoides results from acquired malignant transformation of cutaneous T lymphocytes. No germline causative genes are certified in this packet; the condition does not follow a Mendelian inheritance pattern. The precise molecular events driving malignant transformation are an active area of investigation.

Specific diagnostic criteria are not detailed in this packet. Evaluation of characteristic skin lesions combined with histopathologic assessment is central to clinical recognition; methodology specifics are not certified in the current record.

Five FDA-approved treatments are documented in this packet for mycosis fungoides: methotrexate (JYLAMVO), cyclophosphamide, mogamulizumab-kpkc (POTELIGEO), mechlorethamine hydrochloride (VALCHLOR), and brentuximab vedotin (ADCETRIS). Several additional agents carrying orphan drug designation specifically for mycosis fungoides or cutaneous T-cell lymphoma indications are under active investigation.

Certified population-level natural history data are not available in this packet. Disease course in mycosis fungoides is variable across the patient population; specific outcome data are not certified in this record.

Mycosis fungoides is an active area of clinical investigation, with numerous trials currently registered on ClinicalTrials.gov. Ongoing studies include investigations of novel agents, combination approaches, and cell-based therapies in the CTCL setting. Active clinical trials for this condition are listed on ClinicalTrials.gov.